Indranil Nandi

20040068000, Apr 8, 2004

Oct 2, 2002

10/263161

Mintong Guo - Plainsboro NJ, US
Indranil Nandi - Plainsboro NJ, US
Ashish Patel - Kendall Park NJ, US
Chuanbin Wu - Franklin Park NJ, US

A61K031/405
A61K009/20

514/419000

A pharmaceutical composition for oral administration comprising a compression coated solid dosage form of a bitter or unpleasant tasting pharmaceutically active agent. Included are compression coated oral dosage forms of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide or a pharmaceutically acceptable salt or solvate thereof as active ingredient. The compression coated solid dosage forms are of use in the treatment of conditions associated with cephalic pain, in particular migraine.

20050008704, Jan 13, 2005

Jul 11, 2003

10/618545

Anup Ray - Staten Island NY, US
Indranil Nandi - Plainsboro NJ, US
Suresh Palaniswamy - East Windsor NJ, US
Pablo Davila - East Windsor NJ, US
Aakanksha Vora - Dayton NJ, US

A61K031/704
A61K031/56
A61K031/5513
A61K031/58

424486000, 514171000, 514649000, 514035000, 514221000, 514571000, 514616000, 514174000

The present invention provides a pharmaceutical composition having enhanced solubility comprising a drug and polyethylene glycol, wherein the ratio of polyethylene glycol to drug by weight is from about 0.2:1 to about 10:1, and the polyethylene glycol has a melting point of at least 37 C. The pharmaceutical compositions exhibit rapid dissolution upon contact with physiological solvents, such as water, saliva or gastrointestinal fluids.

20050065183, Mar 24, 2005

Jul 31, 2003

10/631874

Indranil Nandi - Plainsboro NJ, US
Ashish Patel - Kendall Park NJ, US
Mohsen Sadatrezaei - Allentown PA, US
Pablo Davila - East Windsor NJ, US

A61K031/445

514317000, 514053000

A pharmaceutical composition comprising fexofenadine or a pharmaceutical acceptable salt thereof, about 10 wt. % to about 70 wt. % of lactose, and about 1 wt. % to about 40 wt. % of a low-substituted hydroxypropyl cellulose, wherein the weight percents are based on the total weight of the pharmaceutical composition. The fexofenadine compositions of the invention exhibit improved bioavailability as expressed as C, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve.

20050084540, Apr 21, 2005

Oct 17, 2003

10/688551

Indranil Nandi - Plainsboro NJ, US
Mintong Guo - Plainsboro NJ, US
Chad Gassert - Hoboken NJ, US

A61K009/16
A61K009/50

424490000

A taste masking composition comprising micropellets containing an antibiotic wherein said micropellets have an inner coating comprising at least one cellulose polymer which is not an enteric coating polymer and an outer coating comprising an enteric coating polymer, wherein said micropellets have a particle size of about 100 μm to about 650 μm. The micropellets are characterized by (i) a lack of bitter taste; (ii) fast dissolution; and (iii) increased bioavailability of antibiotic as compared to antibiotic containing pellets having a drug-polymer matrix.

20050084541, Apr 21, 2005

Jan 30, 2004

10/768562

Indranil Nandi - Plainsboro NJ, US
Mintong Guo - Plainsboro NJ, US
Chad Gassert - Hoboken NJ, US
Franz Schwarz - Woergl, AT
Irina Kosilek - Kufstein, AT

A61K009/24
A61K009/16
A61K009/50

424490000

An oral suspension comprising (a) an antibiotic composition which comprises coated micropellets and optionally one or more excipients, (b) additional excipients, and (c) a solvent, wherein said coated micropellets comprise (i) a core comprising at least one antibiotic; (ii) an inner coating comprising at least one cellulose polymer which is not an enteric coating polymer; and (iii) an outer coating comprising at least one enteric coating polymer, wherein said coated micropellets have a mean particle size of about 100 μm to about 650 μm. The oral suspension of the invention is characterized by a lack of bitter taste.

20050181043, Aug 18, 2005

Feb 12, 2004

10/779050

Indranil Nandi - Plainsboro NJ, US
Pablo Davila - East Windsor NJ, US
Theodore Burnell - Superior CO, US

A61K031/66
A61K009/20

424464000, 514102000

A tablet composition comprising an alendronate salt and optionally one or more excipients, wherein the cumulative total of the alendronate salt particles in the composition have a particle size distribution as follows: (a) about 19% to about 25% of the particles have a particle size of 250 microns as determined by a U.S. Sieve No. 60; (b) about 14% to about 17% of the particles have a particle size of 180 microns as determined by a U.S. Sieve No. 80; (c) about 10% to about 13% of the particles have a particle size of about 150 microns as determined by a U.S. Sieve No. 100; (d) about 16% to about 23% of the particles have a particle size of 90 microns as determined by a U.S. Sieve No. 170; (e) about 9% to about 17% of the particles have a particle size of 75 microns as determined by a U.S. Sieve No. 250; (f) about 13% to about 16% of the particles have a particle size of 45 microns as determined by a U.S. Sieve No. 325; and (g) about 1% to about 10% of the particles have a particle size of less than 45 microns, wherein the weight percents are based on the total weight of the alendronate salt. The tablets do not require lactose or polyvinylpyrrolidone in order to achieve blend uniformity.

20050181052, Aug 18, 2005

Feb 17, 2004

10/779933

Satishkumar Patel - West Windsor NJ, US
Indranil Nandi - Plainsboro NJ, US
Suresh Palaniswamy - East Windsor NJ, US
Pablo Davila - East Windsor NJ, US

A61K031/4439
A61K009/48
A61K009/20
A61K009/24

424472000, 514338000

A pharmaceutical composition comprising microtablets, wherein said microtablets comprise lansoprazole, a lubricant, optionally one or more excipients, and an enteric coating, wherein the weight ratio of lansoprazole to lubricant is from about 1:4 to about 8:1, wherein said microtablets have a tablet size of about 1 mm to about 4 mm, and a tablet weight of 1 to 50 mg, and said microtablets are free of a separating or intermediate layer between the lansoprazole and enteric coating.

20060193915, Aug 31, 2006

Feb 6, 2006

11/348286

Mintong Guo - Plainsboro NJ, US
Indranil Nandi - Plainsboro NJ, US
Ashish Patel - Kendall Park NJ, US
Chuanbin Wu - Franklin Park NJ, US

A61K 31/404
A61K 9/24

424472000, 514419000

A pharmaceutical composition for oral administration comprising a compression coated solid dosage form of a bitter or unpleasant tasting pharmaceutically active agent. Included are compression coated oral dosage forms of 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide or a pharmaceutically acceptable salt or solvate thereof as active ingredient. The compression coated solid dosage forms are of use in the treatment of conditions associated with cephalic pain, in particular migraine.